| Quarter ₩bn | Revenue | YoY | Operating income | Margin | YoY | Net income | EPS |
|---|---|---|---|---|---|---|---|
| 2026 Q2 | 24.4 | +158.7% | 2.8 | 11.4% | +150.6% | 3.8 | ₩83 |
| 2026 Q1 | 23.0 | +150.6% | 4.6 | 20.0% | +190.6% | 6.4 | ₩141 |
| 2025 Q4 | 15.6 | — | 1.6 | 10.3% | — | 4.7 | ₩103 |
| 2025 Q3 | 19.2 | — | 8.3 | 43.3% | — | 9.4 | ₩207 |
| 2025 Q2 | 9.4 | — | 1.1 | 11.8% | — | -0.2 | ₩-3 |
| 2025 Q1 | 9.2 | — | 1.6 | 17.2% | — | 1.9 | ₩41 |
| 2024 Q4 | — | — | — | — | — | — | — |
| Fiscal year ₩bn | Revenue | YoY | Operating income | Margin | YoY | Net income | EPS |
|---|---|---|---|---|---|---|---|
| FY2025 | 53.4 | +259.8% | 12.6 | 23.6% | — | 15.8 | ₩348 |
| FY2024 | 14.8 | -29.5% | -4.8 | -32.3% | -315.1% | -8.1 | ₩-178 |
| FY2023 | 21.1 | +22,064.2% | 2.2 | 10.6% | — | 1.7 | ₩37 |
| FY2022 | 0.1 | — | -14.8 | -15,618.5% | — | -14.4 | ₩-318 |
The latest quarter on file is 2026 Q2. The next one, the Q3 2026 report covering the period to Sep 30, 2026, is due on DART by Nov 14, 2026 — Korean issuers must file quarterly and half-year reports within 45 days of period end and the annual report within 90 days.
Large issuers usually publish preliminary consolidated figures (잠정실적, a fair-disclosure filing with revenue and operating profit only) in the first weeks after the period ends, ahead of the full report. kstock does not know a company's chosen release date; when the preliminary filing arrives it appears under Filings and on this page.
| Symbol | Last Price |
|---|---|
| 185750Chong Kun Dang Pharmaceutical Corp. | ₩68,000 -0.3% |
| 115180Qurient Co., Ltd. | ₩23,050 +17.3% |
| 476830Rznomics, Inc. | ₩28,200 +6.8% |
| 003850Boryung Corporation | ₩9,040 +1.6% |
| 950260Ingenia Therapeutics Inc.(reg.s) | ₩15,580 -1.5% |
| 085660Chabiotech Co., Ltd. | ₩8,090 +2.1% |
| 041960Komipharm International Co., Ltd. | ₩9,710 +3.5% |
| 317450Myungin Pharm | ₩44,650 +0.0% |
| 001060JW Pharmaceutical | ₩27,500 +1.3% |
| 456160G2GBIO, Inc. | ₩37,950 +5.7% |